Skip to content

Comparison of the Clinical Efficacy, Adverse Effects, and Patient Satisfaction Between Ciprofol Combined with Etomidate Versus Propofol Combined with Etomidate in Painless Gastrointestinal Endoscopy

Propofol versus Ciprofol for Painless Gastrointestinal Endoscopy: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107221
Enrollment
Unknown
Registered
2025-08-06
Start date
2023-10-12
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Gastrointestinal Endoscopy

Interventions

Ciprofol-Etomidate group (C-E group):1ml of ciprofol is approximately equivalent in efficacy to 1ml of propofol. The bolus dose (in ml) is calculated as body weight × 2.5 ÷ 10 (based on the pure propo
Propofol-Etomidate group (P-E group):The bolus dose (in ml) is calculated as body weight × 2.5 ÷ 10 (based on the pure propofol regimen). For the propofol-etomidate group (P-E group), the initial bolu

Sponsors

Wuxi No.2 People's Hospital, Affiliated Central Hospital of Jiangnan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Eligibility for sedation confirmed through preliminary preoperative anesthesia evaluation; 2.Age of 18–80 years; 3.ASA (American Society of Anaesthesiologists) grade I–?; 4.Capacity to engage in logical dialogue and address study-related questions pertinently.

Exclusion criteria

Exclusion criteria: 1.New-onset hemodynamic instability; 2.The patient opted against sedation after detailed counseling; 3.Documented psychiatric disorders via medical history review.

Design outcomes

Primary

MeasureTime frame
Hemodynamic indicators (blood pressure, heart rate, SpO2);CFQ frailty scores when OAA/S score =4;

Secondary

MeasureTime frame
Time from drug administration to loss of eyelash reflex;Total drug administration duration;Presence of severe coughing during gastroscope insertion;Occurrence of intense body movements requiring repeated supplemental doses for suppression;

Countries

China

Contacts

Public ContactZhen Gu

Wuxi No.2 People's Hospital, Affiliated Central Hospital of Jiangnan University

guzhen0304@163.com+86 188 0057 0154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 26, 2026